Generic Janumet® (Zita-Met Tablets) – Product Information
Generic Janumet® (Zita-Met tablets, manufactured by Glenmark Pharmaceuticals) is a prescription medicine that contains two prescription diabetes medicines, Sitagliptin Phosphate (Generic Januvia®) and Metformin HCl. Generic Janumet® can be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Generic Janumet (Zita-Met Tablets) - Active Ingredients
The active ingredients present in Generic Janumet® are Sitagliptin Phosphate and Metformin HCl.
Dosage And Administration
Zita-Met comes as an oral tablet in Sitagliptin 50 mg / Metformin 500 mg dosage form.
The dosage of anti-hyperglycaemic therapy with Generic Janumet should be individualised on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin.
Generic Janumet should generally be given twice daily with meals, with gradual dose escalation, to reduce the gastrointestinal (GI) adverse effects associated with metformin. The starting dose of Zita-Met (Generic Janumet) is usually Sitagliptin (50 mg) + Metformin (500mg) twice daily with meals.
Generic Janumet (Zita-Met Tablets) - Contraindications
Generic Janumet is contraindicated in persons who have shown hypersensitivity to the active ingredients Sitagliptin Phosphate, Metformin HCl or any inactive ingredients of this formulation. It is also contraindicated in individuals with Renal dysfunction, e.g., serum creatinine equal to or greater than 1.5 mg/dL [males], equal to or greater than 1.4mg/dL [females] or abnormal creatinine clearance. Generic Janumet is also contraindicated in cases of Metabolic acidosis, including diabetic ketoacidosis.
Generic Janumet (Zita-Met Tablets) - Warnings
Lactic acidosis: The patient should be warned against excessive alcohol intake. Generic Janumet is not recommended in hepatic impairment and is contraindicated in renal impairment. Ensure normal renal function before initiating and at least annually thereafter.
Radiologic Studies: Temporarily discontinue Generic Janumet in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food or fluids.
Acute Pancreatitis: There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue Generic Janumet (Zita-Met tablets).
Renal Failure: There have been postmarketing reports of acute renal failure, sometimes requiring dialysis. Before initiating Generic Janumet (Zita-Met tablets)and at least annually thereafter, assess renal function and verify as normal.
Vitamin B12 Deficiency: Metformin may lower Vitamin B12 levels. Measure hematologic parameters annually.
Risk Of Hypoglycemia: When used with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia.
Side Effects of Generic Janumet (Zita-Met Tablets)
The common side effects reported in 1% or more of patients receiving combination therapy of Sitagliptin Phosphate and Metformin HCl (Generic Janumet) are Diarrhoea, Headache, Nausea, Upper respiratory tract infections, Dyspepsia, Flatulence, Vomiting, Gastrointestinal adverse reactions, Hypoglycaemia on concomitant use with other anti-diabetic drugs and Allergic reactions.
More Details
For more details on Generic Janumet please read the prescription information or watch the presentation below.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.